Associations between bolus infusion of hydrocortisone, glycemic variability and insulin infusion rate variability in critically Ill patients under moderate glycemic control by unknown
van Hooijdonk et al. Ann. Intensive Care  (2015) 5:34 
DOI 10.1186/s13613-015-0077-5
RESEARCH
Associations between bolus infusion 
of hydrocortisone, glycemic variability 
and insulin infusion rate variability in critically Ill 
patients under moderate glycemic control
Roosmarijn T. M. van Hooijdonk1*, Jan M. Binnekade1, Lieuwe D. J. Bos1,2, Janneke Horn1, Nicole P. Juffermans1,2, 
Ameen Abu‑Hanna3 and Marcus J. Schultz1,2
Abstract 
Background: We retrospectively studied associations between bolus infusion of hydrocortisone and variability of the 
blood glucose level and changes in insulin rates in intensive care unit (ICU) patients.
Methods: ‘Glycemic variability’ and ‘insulin infusion rate variability’ were calculated from and expressed as the stand‑
ard deviation (SD) of all blood glucose levels and insulin infusion rates during stay in the ICU, respectively. Glycemic 
and insulin infusion rate variability in patients who received bolus infusion of hydrocortisone were compared to those 
in patients who never received bolus infusion of hydrocortisone. Multivariate analysis was performed to correct for 
potential covariates including disease severity.
Results: We included 6409 patients over 6 years; of them 962 received bolus infusion of hydrocortisone. Compared 
to patients who never received bolus infusion of hydrocortisone, patients who received hydrocortisone had their 
blood glucose level measured more frequently, had higher glycemic variability; were more frequently treated with 
intravenous insulin and had higher insulin infusion rate variability. The association between hydrocortisone treatment 
and glycemic variability was independent of disease severity, but the effect of hydrocortisone treatment on blood 
glucose variability was less strong in the more severely ill patients. The association between hydrocortisone and insu‑
lin infusion rate variability was also independent of disease severity, and independent of glycemic variability.
Conclusions: Bolus infusion of hydrocortisone is independently associated with higher glycemic variability and 
higher insulin infusion rate variability in ICU patients. Studies are needed to see if continuous infusion of hydrocorti‑
sone prevents higher glycemic variability and higher insulin infusion rate variability.
Keywords: Hydrocortisone, Bolus infusion, Blood glucose control, Glycemic control, Blood glucose variability, Insulin, 
Insulin infusion rate variability
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Background
Low-dose hydrocortisone treatment is an accepted ther-
apy for patients with refractory shock [1]. Bolus infusion 
of hydrocortisone, however, could induce short epi-
sodes of hyperglycemia frequently requiring temporary 
adjustments of the insulin infusion rate in critically ill 
patients [2, 3]. While experienced intensive care unit 
(ICU) nurses usually are capable of preventing large 
swings in the blood glucose level [4], they could be less 
skilled in avoiding hydrocortisone-induced dysglycemia. 
Furthermore, preventing hydrocortisone-induced dys-
glycemia could largely increase nurse labor and costs 
associated with blood glucose monitoring, as temporary 
adjustments of insulin infusion rates could also increase 
the frequency of blood glucose measurements [3, 5]. 
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Notably, glycemic variability is associated with increased 
mortality in critically ill patients [6].
It is unknown to what extent bolus infusion of hydro-
cortisone increases glycemic variability and adjustments 
in insulin infusion rates in patients under moderate gly-
cemic control. Therefore, in a cohort of patients receiv-
ing blood glucose control aiming at blood glucose levels 
between 90 and 144 mg/dL, we tested the two following 
hypotheses: (a) bolus infusion of hydrocortisone is asso-
ciated with glycemic variability, and (b) bolus infusion of 




This was a retrospective cohort study performed in a 
32-bed mixed medical-surgical ICU in a university hos-
pital in the Netherlands (the Academic Medical Center, 
Amsterdam, The Netherlands). The Institutional Review 
Board approved the study protocol and waived the need 
for individual patient consent or ethical approval to col-
lect and analyze data from registries that exclude patient-
identifying information.
Study setting
The ICU was a closed-format unit with patients under 
the direct care of a team of board-certified ICU nurses 
and physicians. The nurse to patient ratio was 1:2. All 
beds were equipped with the MetaVision® patient data 
management system (iMDsoft, Tel Aviv, Israel) in which 
all blood glucose levels and insulin infusion rates were 
stored automatically.
Blood glucose control
The local guideline for moderate blood glucose control 
did not change during the period of data collection, 
and has been described before [7–9]. In short, experi-
enced ICU nurses carefully titrated insulin aiming at 
a blood glucose level between 90 and 144  mg/dL. For 
this, continuous insulin infusion was started when the 
blood glucose level exceeded 144  mg/dL, and adjust-
ments were made following a flow chart (see Addi-
tional file 1). Insulin infusion was stopped, and a bolus 
of 50 mL dextrose 20 % was given when the blood glu-
cose level dropped <63 mg/dL. The flow chart provided 
recommendations regarding timing of follow-up blood 
glucose measurement, which could vary from 20 min to 
4 h. Blood glucose levels were exclusively measured in 
blood samples obtained via an arterial catheter using a 
RapidLab 1265 blood gas analyzer (Siemens Healthcare 
Diagnostics, The Hague, The Netherlands) located in 
the ICU.
Indications for and protocol of hydrocortisone therapy
Indications for bolus infusions of hydrocortisone did not 
change during the period of data collection. ICU physi-
cians prescribed bolus infusion of hydrocortisone in 
patients with refractory shock, defined as shock that was 
non-responsive to fluid resuscitation and poorly respon-
sive to vasopressor therapy. Bolus infusion of hydrocorti-
sone started at 100 mg every 8 h for 1 week, after which it 
was slowly tapered, according to international guidelines 
[10]. Bolus infusion of hydrocortisone was also initiated 
in patients with proven or suspected adrenal insuffi-
ciency, e.g., patients who received longstanding treat-
ment with glucocorticosteroids before ICU admission.
Study population
The study cohort consisted of patients admitted to the 
ICU during a six-year period, lasting from January 2007 
to December 2012. Patients <18  years old, readmitted 
patients and patients who were discharged alive within 
24  h were excluded from the analysis. Furthermore, we 
excluded patients who had their blood glucose level 
measured fewer than three times during the entire stay 
in the ICU. Finally, patients who received treatment with 
glucocorticosteroids other than hydrocortisone, and 
patients who received continuous infusion instead of 
bolus infusion of hydrocortisone were excluded.
Data collected
Blood glucose levels, insulin infusion rates and boluses 
of hydrocortisone were extracted from the patient data 
management system. Demographic data were extracted 
from the National Intensive Care Evaluation (NICE) 
database, a validated database with high quality of data 
maintained by the NICE Foundation [11], including gen-
der, age, length, weight, admission diagnosis, admission 
type, the Acute Physiology and Chronic Health Evalua-
tion (APACHE) II score [12], ICU length of stay, hospital 
length of stay, ICU and hospital mortality.
Primary and secondary endpoints
The primary endpoint was glycemic variability. The sec-
ondary endpoints were the insulin infusion rate vari-
ability and the number of blood glucose measurements 
during stay in ICU. Glycemic variability was calculated 
from and expressed as the SD of all blood glucose lev-
els per patient over the entire stay in ICU, as described 
before [6, 13] and as recommended in the consensus 
guidelines [14]. We chose to use the SD, as this is the 
most frequently used metric for glycemic variability. 
Insulin infusion rate variability was calculated from and 
expressed as the SD of insulin infusion rates per patient 
over the entire stay in ICU.
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Power analysis
We did not perform a power calculation, as this was a 
retrospective observational exploratory analysis. We 
assumed to have sufficient numbers of patients when 
including the whole cohort over a period of 6 years.
Analysis plan
Demographic, blood glucose and insulin metrics were 
summarized and compared between patients who did 
and did not receive a bolus infusion of hydrocortisone 
during ICU admission. Data were compared using the 
Student’s t test, the Mann–Whitney U test or the Chi-
Square test. Statistical significance was considered to be 
at a P value <0.05. When appropriate, statistical uncer-
tainty was expressed by the 95 % confidence levels.
We used univariate and multivariate linear regres-
sion analysis to test whether bolus infusion of hydro-
cortisone was independently associated with increased 
glycemic variability and insulin infusion rate variability. 
For this, glycemic variability was logarithmically trans-
formed (using the natural logarithm) to obtain a more 
normal distribution. We categorized insulin infusion rate 
variability to ‘no insulin infusion rate variability’ (which 
included patients who never received insulin during the 
entire stay in ICU, and patients with fewer than three 
changes in the insulin infusion rate), and the three ter-
tiles of the SD of the insulin infusion rate.
Thus, two separate multivariate models were devel-
oped, one model for glycemic variability and one model 
for insulin infusion rate variability. We first investigated 
if disease severity, expressed as the APACHE II score, 
was a significant interaction term with hydrocortisone. 
We stratified for the APACHE II scores into three groups 
[15, 16], when the P value of the interaction term was 
significant and the model fit improved (based on Akaike 
Information Criterion). The models included variables 
that were established as confounders [17]. A confounder 
was defined as a variable that is not on the casual path 
between hydrocortisone infusion and glycemic or insulin 
variability. Thus, for instance, we did not include vaso-
pressor use as we considered it likely that vasopressor 
use is on the casual path. The following variables were 
tested for confounding: gender, BMI and type of admis-
sion (non-surgical, elective surgery, emergency surgery). 
All these variables met the theoretical criteria for con-
founding because they are (surrogate) causes or risk fac-
tors of outcome; and associated with the exposure (but 
not affected by it) [17].
Correlation between covariates was assessed to investi-
gate collinearity. Pearson correlation coefficients were all 
under 0.5 showing no significant collinearity. The effect 
of covariates on the glucose variability was reported as 
the percentage of change in the glucose variability with 
the confidence interval. The effects of covariates on the 
insulin infusion rate variability were reported as odds 
ratios with the 95 % confidence interval. This odds ratios 
represent the odds of having a high insulin infusion rate 
variability (the highest tertile of the SD) compared to 
having no variability, or a small or moderate insulin infu-
sion rate variability (the lowest and middle tertile of the 
SD), the odds of having moderate and high insulin infu-
sion rate variability versus no or small insulin infusion 
rate variability, and the odds of having small, moderate 
and high insulin infusion variability rate versus having 
no variability. Finally, an ordinal regression was made to 
test if bolus infusion of hydrocortisone, independently of 
glycemic variability, was associated with insulin infusion 
rate variability.
In a post hoc analysis, we used the glycemic lability 
index (GLI) for glycemic variability, as this metric for 
glycemic variability takes into account the time interval 
between measurements [18]. The median GLI per day 
per patient was used in the analysis.
Diabetic status can be a potential confounder, but dia-
betic status was not captured, or captured incompletely, 
in the first 2 years of the cohort. We performed a second 
post hoc analysis, including only patients in whom dia-
betic status was reliably captured.
Analyses were performed using R (version: 3.1.1; R 
Foundation for Statistical Computing, Vienna, Austria).
Results
Patients
Of 11,946 patients 4638 met the exclusion criteria for 
the present analysis (Fig. 1). One hundred eighty patients 
had fewer than three blood glucose measurements avail-
able, necessary to calculate glycemic variability, and 718 
patients received treatment with other glucocorticoster-
oids than hydrocortisone. Continuous infusion of hydro-
cortisone was never used. Table  1 shows demographic 
data of the remaining 6409 patients. Patients treated with 
hydrocortisone were older, more severely ill according to 
APACHE II scores, more often non-surgical patients and 
died more frequently.
Blood glucose metrics and insulin infusion metrics
Hypoglycemia and hyperglycemic measurements were 
more frequently found in patients treated with bolus 
infusions of hydrocortisone (Table 2). Glycemic variabil-
ity was higher in patients who received hydrocortisone. 
The total number of blood glucose measurements dur-
ing stay in ICU, and the median number of blood glu-
cose measurements per day was higher in patients who 
received hydrocortisone.
Patients treated with bolus infusions of hydrocortisone 
were treated with insulin more frequently (Table 3). They 
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received more boluses of insulin, and had more frequent 
adjustments in the insulin infusion rate. Consequently, 
they had higher insulin infusion rate variability.
Univariate and multivariate analyses
Tables  4 and 5 detail the results for the univariate and 
multivariate analyses. For all the three models, APACHE 
II score was a significant interaction term and therefore 
the analysis was stratified per APACHE II score category. 
In all three APACHE II score categories, bolus infusion of 
hydrocortisone was independently associated with higher 
glycemic variability expressed as the SD, though the effect 
was less strong in more severely ill patients.
Patients who received bolus infusion of hydrocortisone 
had higher odds of having higher insulin infusion rate 
variability, independently of confounders. The associa-
tion between bolus infusion of hydrocortisone and insulin 
infusion rate variability remained statistically significant 
when glycemic variability was included as confounder.
Post hoc analyses
In the first post hoc analysis, bolus infusion of hydrocor-
tisone was independently associated with higher GLI in 
the group of patients with APACHE II score between 15 
and 24 (Additional file 1: Table S1). Entering GLI as con-
founder between bolus infusion of hydrocortisone and 
Fig. 1 CONSORT diagram of the study
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Table 1 Patient characteristics
APACHE acute physiology and chronic health evaluation, BMI body mass index, ICU intensive care unit, IQR interquartile range, LOS length of stay
Characteristics Patients who did not receive  
bolus infusion of hydrocortisone  
(N = 5447)
Patients who received bolus  
infusion of hydrocortisone  
(N = 962)
P value Total cohort 
(N = 6409)
Age (years, median [IQR]) 63 [51–73] 65 [55–74] <0.001 63 [52–73]
Male gender [no (%)] 3431 (63.0) 571 (59.4) 0.035 4002 (62.4)
BMI (kg/m2, median [IQR]) 25 [23–28] 25 [23–29] 0.968 25 [23–28]
Admission diagnosis [no (%)] <0.001
 Non‑surgical 2159 (39.6) 542 (56.3) 2701 (42.1)
 Emergency surgery 993 (18.2) 200 (20.8) 1193 (18.6)
 Elective surgery 2295 (42.1) 220 (22.9) 2515 (39.2)
History of diabetes [no (%)]
 Diabetes 550 (14.7) 102 (16.5) 0.281 652 (15.0)
 Non diabetes 3188 (85.3) 517 (83.5) 3705 (85.0)
 Missing values 1709 343 2052
APACHE II scores (median [IQR]) 18 [14–24} 24 [19–30] <0.001 19 [14–25]
SAPS II score 40 [31–52] 55 [44–67] <0.001 42 [32–54]
ICU LOS (days, median [IQR]) 2 [1–4] 6 [3–12] <0.001 3 [2–5]
Hospital LOS (days, median [IQR]) 10 [6–20] 16 [8–36] <0.001 11 [6–22]
ICU mortality [no (%)] 658 (12.1) 306 (31.8) <0.001 961 (15.0)
Hospital mortality [no (%)] 944 (17.3) 391 (40.6) <0.001 1335 (20.8)
Table 2 Blood glucose metrics
IQR interquartile range, IU international units
Patients who did not receive  
bolus infusion of hydrocortisone  
(N = 5447)
Patients who received bolus  
infusion of hydrocortisone  
(N = 962)
P value Total cohort 
(N = 6409)
Number of measurements (median  
[IQR])
20 [13–35] 53 [30–97] <0.001 22 [13–42]
Median number of measurements per 
day (median [IQR])
6 [5–8] 7 [6–9] <0.001 6 [5–8]
Median number of measurements per 
day with hydrocortisone (median  
[IQR])
8 [7–10]
Median number of measurements per 
day without hydrocortisone (median 
[IQR])
6 [4–7]
Mean blood glucose level (mg/dL, 
median [IQR])
136 [125–148] 136 [127–148] 0.043 136 [126–148]
Median blood glucose level (mg/dL, 
median [IQR])
132 [122–144] 132 [123–141] 0.588 132 [123–144]
Standard deviation of blood glucose  
level (mg/dL, median [IQR])
28 [20–39] 35 [26–47] <0.001 29 [21–40]
Glycemic Lability Index  
(mg/dL2/hour/day median [IQR])
942 [371–2236] 1322 [594–2883] <0.001 994 [400–2369]
Maximum blood glucose level  
(mg/dL, median [IQR])
193 [166–234] 231 [193–285] <0.001 198 [169–241]
Minimum blood glucose level  
(mg/dL, median [IQR])
90 [77–101] 70 [56–85] <0.001 88 [74–99]
Mild hypoglycemia, <70 mg/dL (%) 826 (15.2) 451 (46.9) <0.001 1277 (19.9)
Severe hypoglycemia, <40 mg/dL (%) 115 (2.1) 80 (8.3) <0.001 195 (3.0)
Hyperglycemia, >180 mg/dL (%) 3438 (63.1) 824 (85.7) <0.001 4262 (66.5)
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insulin infusion rate variability did not affect the associa-
tion (Additional file 1: Table S2).
In the second post hoc analysis, including only patients 
in whom diabetic status was reliably captured, the asso-
ciation between bolus infusion of hydrocortisone and 
glycemic and insulin variability remained statistically sig-
nificant when diabetic status was included as confounder 
(Additional file 1: Tables S3, S4).
Discussion
The results of this retrospective analysis of blood glu-
cose levels and insulin infusion rates in ICU patients 
under moderate glycemic control show that bolus infu-
sion of hydrocortisone is associated with higher glycemic 
variability and insulin rate variability, more frequent BG 
measurements and a greater need for insulin boluses. 
These associations were independent of several factors, 
Table 3 Insulin metrics
IQR interquartile range, IU international units
Patients who did not receive  
bolus infusion of hydrocortisone  
(N = 5447)
Patients who received infusion 
of hydrocortisone (N = 962)
P value Total cohort 
(N = 6409)
Patients receiving insulin infusion  
[no (%)]
3693 (67.8) 875 (91.0) <0.001 4568 (71.3)
Patients receiving boluses of insulin 
infusion [no (%)]
490 (9.0) 248 (25.8) <0.001 738 (11.5)
Number of insulin rate adjustments 
(median [IQR])
3 [0–8] 17 [6–35] <0.001 4 [0–12]
Median number of insulin rates per  
day (median [IQR])
1 [0–2] 2 [1–3] <0.001 1 [0–2]
Median number of insulin rates per  
day with hydrocortisone (median 
[IQR])
3 [1–4]
Median number of insulin rates  
per day without hydrocortisone 
(median [IQR])
1 [0–2]
Patients in insulin infusion rate vari‑
ability category:
 No insulin infusion rate variability 2494 (45.8) 136 (14.1) 2630 (41.0)
 Small insulin infusion rate variability 887 (16.3) 111 (11.5) 998 (15.6)
 Moderate insulin infusion rate  
variability
1104 (20.3) 260 (27.0) 1364 (21.3)
 High insulin infusion rate variability 962 (17.7) 455 (47.3) 1417 (22.1)
Standard deviation of insulin rate  
(IU/h, median [IQR])
0.6 [0–1.3] 1.6 [0.8–6.2] <0.001 0.7 [0–1.6]
Table 4 Results of univariate and multivariate analysis with glycemic variability
APACHE acute physiology and chronic health evaluation, BMI body mass index, CI confidence interval
a Multivariate model includes the significant confounders Admission Type, and BMI
b Multivariate model includes the significant confounders Admission Type, gender and BMI
c Multivariate model includes the significant confounders Admission Type, and gender
Variable Univariate Multivariate
Percentage of change  
in glycemic variability [95 % CI]
P value Percentage of change 
in glycemic variability [95 % CI]
P value
APACHE II score <15
 Bolus infusion of hydrocortisone 20 [5 – 36] 0.008 23 [8 – 40]a 0.0018
APACHE II score 15–24
 Bolus infusion of hydrocortisone 22 [16 – 29] <0.001 23 [16 – 30]b < 0.001
APACHE II score >24
 Bolus infusion of hydrocortisone 15 [8–21] <0.001 14 [8–20]c < 0.001
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including severity of disease and also diabetic status. One 
salient finding in the present analysis was that the asso-
ciations between bolus infusions of hydrocortisone and 
glycemic variability and insulin infusion rate variability 
were less strong in patients who were more severely ill. 
It could be that the impact of severity of disease on vari-
ability of the blood glucose level and the insulin infusion 
rate is much stronger than the impact of bolus infusions 
of hydrocortisone. This could partly blur the associa-
tions, which we were interested in. Furthermore, when 
GLI was used to express glycemic variability, the inde-
pendent association between bolus infusion and glyce-
mic variability was significant only in patients with an 
APACHE II score between 15 and 24. The GLI takes into 
account the time interval and SD does not, which might 
explain the different results. Still, both measures do not 
capture all glucose excursions, as we were not continu-
ously measuring the glucose level and thereby missing, by 
definition, blood glucose excursions between two glucose 
measurements.
We chose to develop a metric for insulin infusion rate 
variability, a new metric, based on the standard devia-
tion similar to the one we used for glycemic variability. It 
should be noticed that insulin infusion rate variability may 
not reflect changes in insulin resistance or insulin sensitiv-
ity, but it could be a measure indicating changes in nursing 
workload. This was exactly the reason for developing this 
new metric, as most other metrics in the domain of blood 
glucose control do not consider workload by nurses. The 
number of measurements per day was considered before 
as measure indicating the nursing workload [3]. However, 
it is not only the blood glucose measurements which is 
time consuming, also the interpretation of the blood glu-
cose measurement and the change in the insulin infusion 
pump takes time. In addition, trained nurses are necessary 
to perform the blood glucose control or when available 
decision support could be used.
The results are, at least in part, in line with those 
from several previous studies. First, in a randomized 
controlled study in cardiac surgery patients, peropera-
tive treatment with dexamethasone was associated with 
elevated blood glucose levels for as long as 15  h after 
surgery, requiring more intensive treatment with insu-
lin [19]. In addition, in a double-blind placebo-con-
trolled randomized study, it was shown that treatment 
with methylprednisolone was associated with higher 
blood glucose levels and higher daily insulin doses in 
patients with COPD exacerbation needing mechani-
cal ventilation [20]. Interestingly, a recent randomized 
study comparing bolus infusion with continuous infu-
sion of hydrocortisone in septic shock patients showed 
no differences in the mean blood glucose level, but more 
hyperglycemic events and more frequent changes in the 
insulin infusion rate were found in patients receiving 
bolus infusion of hydrocortisone [3]. Higher glycemic 
variability was found in patients treated with hydrocor-
tisone, although the difference with patients not treated 
with hydrocortisone remained statistically insignificant, 
probably due to the small sample size of fewer than 50 
patients. Furthermore, the dosing regimen was differ-
ent as they used a dose of 50 mg every 6 h opposed to 
our regimen of 100  mg hydrocortisone every 8  h. It is 
possible that the higher doses of hydrocortisone in the 
present study result in greater glucose variability and 
this might be the reason why we did find an independ-
ent association. Our investigation confirms the results of 
the randomized controlled trial [3] that bolus infusion 
of hydrocortisone indeed influences glycemic variability 
and insulin infusion dosing.
It was a practice to infuse a bolus of hydrocortisone 
every 8 h, and because of its relatively short half-life time 
of 90 min, we could have expected large swings in blood 
glucose levels and or insulin infusion rates with this 
treatment, depending on how the local guideline of glu-
cose control allowed changes in the insulin infusion rate. 
We were specifically interested in associations between 
hydrocortisone therapy and glycemic variability, as gly-
cemic variability is considered as one of the domains 
Table 5 Results of univariate and multivariate analysis with insulin infusion rate variability
APACHE acute physiology and chronic health evaluation, BMI body mass index, CI confidence interval
a Multivariate model includes the significant confounder BMI
Variable Univariate Multivariate Multivariate including glycemic 
variability
Odds ratio [95 % CI] Odds ratio [95 % CI] Odds ratio [95 % CI]
APACHE II score <15
 Bolus infusion of hydrocortisone 3.8 [2.4–6.0] 4.2 [2.6–6.7]a 4.1 [2.5–6.7]
APACHE II score 15–24
 Bolus infusion of hydrocortisone 4.0 [3.3–4.9] 4.0 [3.3–4.9] 3.6 [2.9–4.4]
APACHE II score >24
 Bolus infusion of hydrocortisone 3.1 [2.6–3.7] 3.1 [2.6–3.7] 3.1 [2.5–3.7]
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for quality of blood glucose control and associated with 
mortality [6, 21]. Previous studies investigating the effect 
of bolus hydrocortisone on the blood glucose levels in 
septic shock patients focused on hyperglycemia and not 
glycemic variability [2, 3, 22]. We are the first to show 
an independent association between bolus infusion of 
hydrocortisone and glycemic variability in a large cohort 
of critically ill patients, though the question remains 
whether prevention of bolus infusion of hydrocortisone-
induced dysglycemia is beneficial. One randomized con-
trolled trial comparing strict blood glucose control with 
conventional blood glucose control in patients receiving 
low-dose hydrocortisone for refractory shock did not 
find clinical benefit from prevention of bolus infusion of 
hydrocortisone-induced dysglycemia [22]. Notably, this 
trial did not report metrics of glycemic variability, mak-
ing it impossible to see whether the intervention in that 
trial truly influenced glycemic variability. Future stud-
ies are necessary to determine whether it is possible to 
prevent hydrocortisone-induced glycemic variability, and 
if so whether this improves outcome. There could be a 
role for continuous glucose monitoring devices that are 
now slowly entering the market, but this certainly needs 
confirmation in future studies as well. Notably, a recent 
retrospective study showed that use of subcutaneous 
continuous glucose monitoring was not associated with 
lower glycemic variability in critically ill patients [23].
The results of the present study clearly show that action 
was required upon hydrocortisone-induced glycemic var-
iability, as the total number of blood glucose level meas-
urements were almost three times as many as in patients 
not receiving hydrocortisone treatment. Furthermore, 
adjustments of the insulin infusion rate occurred much 
more often. While we could not perform a cost analy-
sis, it is clear that costs associated with blood glucose 
monitoring and adjustments of the insulin infusion rate 
in patients treated with hydrocortisone exceed those in 
patients not receiving hydrocortisone. Several studies 
show that continuous infusion of hydrocortisone is asso-
ciated with a less steep rise of the blood glucose level 
than bolus infusion of hydrocortisone [2, 3]. This suggests 
that continuous infusion of hydrocortisone may need less 
frequent blood glucose measurements and adjustments 
of the insulin infusion rate. However, we should bear in 
mind that continuous infusion of hydrocortisone comes 
at a price: it may need an additional lumen of a cen-
tral line or an extra peripheral venous access, but most 
important it mandates, often expensive, syringe pumps.
Strengths of this study include the large cohort of 
patients and blood glucose levels without any change in 
the local guidelines for blood glucose control or indica-
tion for bolus infusion of hydrocortisone. Furthermore, 
the target of the guideline for blood glucose control is 
a commonly used target in other hospitals, increasing 
generalizability of the results. Weaknesses of the pre-
sent study include its retrospective design. Therefore, 
the data cannot support any causal relationship between 
steroid treatment and glycemic or insulin variability. In 
addition, patients receiving boluses of hydrocortisone in 
the study cohort were almost without exception suffer-
ing from septic shock, while most patients not receiv-
ing boluses of hydrocortisone were not. Thus, one 
could argue that differences in blood glucose variability 
between the two patient groups were simply reflecting 
differences induced by septic shock. Important in this 
context is that sepsis may be associated with increased 
glycemic variability [24]. Indeed, patients with sep-
tic shock have increased insulin resistance [25], as also 
suggested by the other metrics of blood glucose control 
in our study. However, while insulin resistance is sug-
gested to be dependent on disease severity [25], this 
was not confirmed here as the effect of hydrocortisone 
treatment on blood glucose variability was independent 
of APACHE II scores. The finding that the associations 
were less strong in more severely ill patients may have 
been caused by already high blood glucose variability in 
these patients. Finally, results could have been different 
when glucocorticosteroids other than hydrocortisone 
would have been used because half-life times and gluco-
corticoid effects differ between various glucocorticoster-
oids agents.
There are several measures to calculate the glycemic 
variability. We used two measures and found that the 
association was only significant for both measures in the 
group of patients with APACHE II score between 15 and 
24. It is possible the results will be different when using 
other measures for glycemic variability [6, 23].
One other major limitation of our analysis is that the 
frequency of the blood glucose level measurements 
affects the SD of the blood glucose level [13]. Never-
theless, in previous investigations, glycemic variabil-
ity remained independently associated with increased 
mortality [6]. Other limitations of this study are its lack 
of data regarding nutritional support and corticosteroid 
usage before ICU admission.
Conclusions
Bolus infusion of hydrocortisone is independently asso-
ciated with increased glycemic variability and increased 
insulin infusion rate variability in ICU patients under gly-
cemic control aiming at blood glucose levels between 90 
and 144 mg/dL. Additional studies are needed to inves-
tigate if the found associations have an affect on mortal-
ity and if continuous infusion of hydrocortisone prevents 
increased blood glucose variability and insulin infusion 
rate variability.
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